Fluvoxamine: The Federal Government Should Invest in Research for Early Stage COVID-19 Treatment

Fluvoxamine The Federal Government Should Invest in Research for Early Stage COVID-19 Treatment

A common selective serotonin reuptake inhibitor and σ-1 receptor agonist, mounting data indicates that fluvoxamine prevents clinical deterioration in outpatients with acute COVID-19. This finding is based on the  peer reviewed published results from a clinical trial involving 152 study participants who were confirmed with SARS-CoV-2-based symptoms within 7 days of study participation. Led by Dr. Eric Lenze and a team from Washington University School of Medicine in St. Louis, the study results indicate yet another important opportunity for a repurposed therapy targeting COVID-19. Although the investigators acknowledge that broader determination of clinical efficacy would require more research, the team was able to demonstrate in this study a statistically significant difference in the fluvoxamine group versus the placebo over 15 days. While the U.S. government continues to invest billions into vaccines and novel therapeutics for COVID-19, data such as this should be triggering considerable activity, including the inclusion of fluvoxamine in the ACTIV-2 study as an example. TrialSite’s Daniel O’Connor was also able to connect with prominent fluvox...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee